Eli Lilly shares moved higher Tuesday after the company previewed late-stage data from its obesity and diabetes pipeline ahead of the 62nd European Association for the Study of Diabetes Annual Meeting in Milan. Phase 3 TRIUMPH-2 results for retatrutide, an investigational triple hormone receptor agonist, showed up to 20.8% average weight loss, or 49.6 pounds, and a 1.6% A1C reduction after 80 weeks in adults with obesity and type 2 diabetes. Phase 3 ACHIEVE-4 data showed Foundayo (orforglipron), Lilly's daily oral GLP-1 treatment, reduced the risk of MACE-3 cardiovascular events by 23% versus insulin glargine. Separately, Phase 1 results for eloraTZP, a combination of eloralintide and tirzepatide, showed 17% weight loss over 16 weeks. The pipeline update follows Lilly's second-quarter 2026 results, which included $22.97 billion in worldwide revenue, a 48% year-over-year increase, and non-GAAP EPS of $8.38. The company raised its full-year 2026 revenue forecast to $85 billion-$87 billion from $82 billion-$85 billion. Shares were up 1.34% at $1,153.50 in premarket trading Tuesday, according to Benzinga Pro data.